Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects. Ten CF subjects received single 180-mg doses of two formulations of MP-376, followed by a multiple-dose phase of 240 mg once daily for 7 days. Ser...

Full description

Saved in:

Bibliographic Details
Published in:	Antimicrobial agents and chemotherapy Vol. 55; no. 6; p. 2636
Main Authors:	Geller, David E, Flume, Patrick A, Griffith, David C, Morgan, Elizabeth, White, Dan, Loutit, Jeffery S, Dudley, Michael N
Format:	Journal Article
Language:	English
Published:	United States 01.06.2011
Subjects:	Administration, Inhalation Adolescent Adult Anti-Bacterial Agents - pharmacokinetics Area Under Curve Cross-Over Studies Cystic Fibrosis - drug therapy Female Humans Levofloxacin Male Middle Aged Ofloxacin - adverse effects Ofloxacin - pharmacokinetics Single-Blind Method Solutions
ISSN:	1098-6596, 1098-6596
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!